Holen Sie sich die Stockscreener-App
0.80
0.74%
-0.006
Vorhandelsmarkt:
.77
-0.03
-3.75%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt DRRX?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$0.806
Offen:
$0.8151
24-Stunden-Volumen:
12,918
Relative Volume:
0.19
Marktkapitalisierung:
$25.02M
Einnahmen:
$8.59M
Nettoeinkommen (Verlust:
$-17.07M
KGV:
-1.3115
EPS:
-0.61
Netto-Cashflow:
$-21.90M
1W Leistung:
-5.77%
1M Leistung:
+2.79%
6M Leistung:
-38.93%
1J Leistung:
-33.88%
1-Tages-Spanne:
$0.80
$0.8151
1-Wochen-Bereich:
$0.80
$0.849
52-Wochen-Spanne:
$0.701
$1.88
Durect Corp Stock (DRRX) Company Profile
Firmenname
Durect Corp
Sektor
Telefon
(408) 777-1417
Adresse
10240 BUBB ROAD, CUPERTINO, CA
Vergleichen Sie DRRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DRRX
Durect Corp
|
0.80 | 25.02M | 8.59M | -17.07M | -21.90M | -0.61 |
|
ZTS
Zoetis Inc
|
163.11 | 73.07B | 9.26B | 2.49B | 2.30B | 5.47 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.05 | 47.43B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
HLN
Haleon Plc Adr
|
10.24 | 45.72B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
15.08 | 17.28B | 16.54B | -1.64B | 749.00M | -1.45 |
UTHR
United Therapeutics Corp
|
306.97 | 14.37B | 2.76B | 1.11B | 898.10M | 22.77 |
Durect Corp Stock (DRRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2020-10-30 | Eingeleitet | Chardan Capital Markets | Buy |
| 2020-10-12 | Eingeleitet | ROTH Capital | Buy |
| 2020-07-31 | Eingeleitet | Oppenheimer | Outperform |
| 2020-01-31 | Eingeleitet | B. Riley FBR | Buy |
| 2019-11-18 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2019-09-06 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-03-06 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2017-10-20 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2017-10-20 | Bestätigt | Laidlaw | Buy |
| 2017-10-20 | Herabstufung | Stifel | Buy → Hold |
| 2017-07-12 | Hochstufung | Stifel | Hold → Buy |
| 2017-02-28 | Fortgesetzt | H.C. Wainwright | Buy |
| 2016-04-25 | Eingeleitet | Rodman & Renshaw | Buy |
| 2015-05-01 | Bestätigt | Cantor Fitzgerald | Buy |
| 2015-05-01 | Bestätigt | Stifel | Buy |
| 2013-03-25 | Eingeleitet | Stifel | Buy |
| 2012-11-01 | Herabstufung | C.K. Cooper | Buy → Hold |
| 2012-08-17 | Eingeleitet | C.K. Cooper | Buy |
| 2009-06-23 | Eingeleitet | Caris & Company | Buy |
| 2009-03-26 | Eingeleitet | Wedbush Morgan | Hold |
Alle ansehen
Durect Corp Aktie (DRRX) Neueste Nachrichten
DURECT Corporation (NASDAQ:DRRX) Q4 2024 Earnings Call Transcript - Insider Monkey
Here's Why We're A Bit Worried About DURECT's (NASDAQ:DRRX) Cash Burn Situation - Yahoo Finance
DURECT Corporation’s Earnings Call Highlights Cost Cuts and Breakthrough Potential - TipRanks
Durect Corp Q4 2024 Earnings: EPS of $0.25 Surpasses Estimates, Revenue Falls Short at $0.5 Million - GuruFocus.com
Durect Corp (DRRX) Q4 2024 Earnings Call Highlights: Strategic Focus Amid Financial Challenges - Yahoo Finance
Durect Corp (DRRX) Q4 2024 Earnings Call Highlights: Strategic F - GuruFocus.com
Durect: Q4 Earnings Snapshot - mySA
Durect reports Q4 cont ops EPS (6c), consensus (2c) - TipRanks
Durect (DRRX) Reports Q4 Loss, Lags Revenue Estimates - MSN
Earnings call transcript: Durect’s Q4 2024 revenue drops as focus shifts to key drug - Investing.com India
DURECT Corp reports results for the quarter ended December 31Earnings Summary - TradingView
DURECT Transforms Business: $17.5M Asset Sale, NEJM Evidence Validates Key Drug Program - StockTitan
Earnings Scheduled For March 26, 2025 - Benzinga
What To Expect From Durect Corp (DRRX) Q4 2024 Earnings - GuruFocus.com
DURECT Corporation to Announce Fourth Quarter and Full Year 2024 - GuruFocus.com
DURECT Corporation to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide a Business Update - Quantisnow
DURECT (DRRX) to Release Quarterly Earnings on Wednesday - Defense World
DURECT Q4 Earnings Preview: Key Financial Results and Strategic Updates Coming March 26 - StockTitan
StockNews.com Begins Coverage on DURECT (NASDAQ:DRRX) - Defense World
DURECT Corporation (NASDAQ:DRRX) Is Expected To Breakeven In The Near Future - Simply Wall St
Wnt efforts condensing at Dewpoint, Surrozen, more - BioWorld Online
Larsucosterol flops on clinical benefit in phase 2b alcohol-associated hepatitis trial - Healio
DURECT (NASDAQ:DRRX) Earns Sell Rating from Analysts at StockNews.com - Defense World
The R&D Dept.: Local patent roundup for 2.26.25 - RichmondBizSense
DURECT (NASDAQ:DRRX) Coverage Initiated at StockNews.com - Defense World
DURECT (NASDAQ:DRRX) Research Coverage Started at StockNews.com - Defense World
DURECT Corporation to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference - Yahoo Finance
Exclusive Healthcare Conference Alert: DURECT CEO Reveals Latest Developments - StockTitan
StockNews.com Initiates Coverage on DURECT (NASDAQ:DRRX) - Defense World
DURECT Corporation Announces Publication of Larsucosterol Phase 2b Results in NEJM Evidence - Stockhouse Publishing
DURECT (NASDAQ:DRRX) Coverage Initiated by Analysts at StockNews.com - Defense World
Durect (DRRX) Upgraded to Strong Buy: Here's Why - Yahoo Finance
Geode Capital Management LLC Has $429,000 Holdings in DURECT Co. (NASDAQ:DRRX) - Defense World
DURECT faces Nasdaq delisting over share price - Investing.com
New Strong Buy Stocks for January 9th - Yahoo Finance
Reviewing Acerus Pharmaceuticals (OTCMKTS:TRLPF) and DURECT (NASDAQ:DRRX) - Defense World
Microbial Products Market Size to Hit USD 351.42 Bn by 2034 - Precedence Research
Durect (DRRX) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
DURECT Corp expected to post a loss of 17 cents a shareEarnings Preview - XM
Is BellRing Brands (BRBR) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
DURECT Corp sells ALZET product line to Lafayette - TradingPedia
Durect announces sale of Alzet line of osmotic pumps to LIC for $17.5M - TipRanks
DURECT Corporation Announces Sale of ALZET® Product Line to Lafayette Instrument Co. for $17.5 Million - PR Newswire
DURECT Corporation (NASDAQ:DRRX) Q3 2024 Earnings Call Transcript - Insider Monkey
Earnings call: DURECT Corporation reports Q3 2024 financials - Investing.com
Durect Corp (DRRX) Q3 2024 Earnings Call Highlights: Revenue Gro - GuruFocus.com
Durect Corp (DRRX) Q3 2024 Earnings Call Highlights: Revenue Growth Amid Cost Reductions and ... - Yahoo Finance
Durect Corp (DRRX) Q3 2024 Earnings Call Highlights: Revenue Growth Amid Cost Reductions and ... By GuruFocus - Investing.com Canada
Durect: Q3 Earnings Snapshot - Houston Chronicle
Durect Corp Q3 2024 Earnings: GAAP EPS of -$0.14 Misses Estimates, Revenue at $1.9 Million Below Expectations - GuruFocus.com
Finanzdaten der Durect Corp-Aktie (DRRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.95%
0.05%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):